Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL: A sub-analysis of the Titration and OPtimisation (TOP) registry.
Pfohl M, Pscherer S, Fritsche A, Anderten H, Borck A, Pegelow K, Bramlage P, Seufert J. Pfohl M, et al. Among authors: pegelow k. Diabetes Obes Metab. 2019 Sep;21(9):2169-2173. doi: 10.1111/dom.13768. Epub 2019 May 29. Diabetes Obes Metab. 2019. PMID: 31069944
Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
Pfohl M, Siegmund T, Pscherer S, Pegelow K, Seufert J. Pfohl M, et al. Among authors: pegelow k. Vasc Health Risk Manag. 2015 Nov 6;11:569-78. doi: 10.2147/VHRM.S82720. eCollection 2015. Vasc Health Risk Manag. 2015. PMID: 26604774 Free PMC article.
HbA1c target achievement in the elderly: results of the Titration and Optimization trial for initiation of insulin glargine 100 U/mL in patients with type 2 diabetes poorly controlled on oral antidiabetic drugs.
Fritsche A, Anderten H, Pfohl M, Pscherer S, Borck A, Pegelow K, Bramlage P, Seufert J. Fritsche A, et al. Among authors: pegelow k. BMJ Open Diabetes Res Care. 2019 Aug 1;7(1):e000668. doi: 10.1136/bmjdrc-2019-000668. eCollection 2019. BMJ Open Diabetes Res Care. 2019. PMID: 31423316 Free PMC article.
Soluble Fas and Fas-ligand in bladder cancer in vitro and in vivo.
Perabo FG, Mattes RH, Wirger A, Steiner G, Kamp S, Schmidt D, Pegelow K, von Ruecker A, Müller SC. Perabo FG, et al. Among authors: pegelow k. Urol Oncol. 2001 Jul;6(4):163-169. doi: 10.1016/s1078-1439(00)00130-7. Urol Oncol. 2001. PMID: 11418323
30 results